DEXAMETHASONE-INDUCED METABOLIC SYNDROME: RE-EVALUATION OF AN UNDERESTIMATED EXPERIMENTAL MODEL | ||||
| Bulletin of Pharmaceutical Sciences Assiut University | ||||
| Volume 45, Issue 2, December 2022, Page 989-1004 PDF (1.3 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/bfsa.2022.271784 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mohamed M. M. Askar   ; Islam A. A. E-H Ibrahim; Mona F. Mahmoud
| ||||
| Department of Pharmacology and Toxicology, Faculty of Pharmacy, Zagazig University Egypt | ||||
| Abstract | ||||
| Dexamethasone is a fluorinated steroid and a synthetic member of glucocorticoids. It is an approved medication for inflammatory and allergic disorders. Also, it is clinically used in high doses to manage pain associated with metastatic osteolytic lesions. Furthermore, it has a wide array of side effects, particularly at high doses and after prolonged consumption, like; hypertension, hyperglycemia, and dyslipidemia. It is a promising tool for studying the underlying mechanisms of metabolic syndrome and insulin resistance. This review article discusses metabolic syndrome and insulin signaling. In addition, this review article will discuss metabolic-dexamethasone effects on the skeletal muscle, liver, adipose tissue, pancreas, brain, and the cardiovascular system, its underlying mechanisms of action, and the benefits of use, in comparison to the other dietary and chemical models of insulin resistance and type 2 diabetes, to identify new potential pharmacological treatments of the metabolic syndrome and its related complications. | ||||
| Keywords | ||||
| Dexamethasone · Diabetes · Metabolic syndrome · Animal model | ||||
|
Statistics Article View: 406 PDF Download: 639 |
||||
